4TX

5-(2,5-dimethylphenoxy)-2,2-dimethylpentanoic acid

Created:	2015-05-27
Last modified:	2015-08-05

Find Related PDB Entry
2 entries where 4TX is found as a standalone ligand

Help Find related ligands:
Similar Ligands (Stereospecific) Similar Ligands (including Stereoisomers) Similar Ligands (Quick Screen) Similar Ligands (Substructure Stereospecific) Similar Ligands (Substructure including Stereoisomers)

Help

Find related ligands:

Similar Ligands (Stereospecific) Similar Ligands (including Stereoisomers) Similar Ligands (Quick Screen) Similar Ligands (Substructure Stereospecific) Similar Ligands (Substructure including Stereoisomers)

Chemical Details
Formal Charge	0
Atom Count	40
Chiral Atom Count	0
Bond Count	40
Aromatic Bond Count	6

WebGL does not seem to be available.

This can be caused by an outdated browser, graphics card driver issue, or bad weather. Sometimes, just restarting the browser helps. Also, make sure hardware acceleration is enabled in your browser.

For a list of supported browsers, refer to http://caniuse.com/#feat=webgl.

Toggle Hydrogen Toggle Labels

Chemical Component Summary
Name	5-(2,5-dimethylphenoxy)-2,2-dimethylpentanoic acid
Systematic Name (OpenEye OEToolkits)	5-(2,5-dimethylphenoxy)-2,2-dimethyl-pentanoic acid
Formula	C₁₅ H₂₂ O₃
Molecular Weight	250.333
Type	NON-POLYMER

Chemical Descriptors
Type	Program	Version	Descriptor
SMILES	ACDLabs	12.01	c1c(OCCCC(C(=O)O)(C)C)c(ccc1C)C
SMILES	CACTVS	3.385	Cc1ccc(C)c(OCCCC(C)(C)C(O)=O)c1
SMILES	OpenEye OEToolkits	1.9.2	Cc1ccc(c(c1)OCCCC(C)(C)C(=O)O)C
Canonical SMILES	CACTVS	3.385	Cc1ccc(C)c(OCCCC(C)(C)C(O)=O)c1
Canonical SMILES	OpenEye OEToolkits	1.9.2	Cc1ccc(c(c1)OCCCC(C)(C)C(=O)O)C
InChI	InChI	1.03	InChI=1S/C15H22O3/c1-11-6-7-12(2)13(10-11)18-9-5-8-15(3,4)14(16)17/h6-7,10H,5,8-9H2,1-4H3,(H,16,17)
InChIKey	InChI	1.03	HEMJJKBWTPKOJG-UHFFFAOYSA-N

Drug Info: DrugBank

DrugBank ID	DB01241
Name	Gemfibrozil
Groups	approved
Description	Gemfibrozil is a fibric acid agent, similar to [clofibrate], used to treat Type IIb, IV, and V hyperlipidemias.[A185777,L8525] Gemfibrozil is not a first line treatment and is prescribed to patients who have not responded adequately to weight loss, diet, exercise, and other medications.[L8525] Gemfibrozil was granted FDA approval on 21 December 1981.[L8525]
Synonyms	2,2-Dimethyl-5-(2,5-xylyloxy)valeric acid Gemfibrozilo Gemfibrozilum Gemfibrozil 2,2-Dimethyl-5-(2,5-xylyloxy)valeriansäure 2,2-Dimethyl-5-(2,5-dimethylphenoxy)valeriansäure
Brand Names	Nu-gemfibrozil Cap 300mg Apo-gemfibrozil Cap 300mg USP Lopid Cap 300mg PHL-gemfibrozil Gemfibrozil Cap 300mg Mylan-gemfibrozil PMS-gemfibrozil Lopid 600mg Gemfibrozil Penta-gemfibrozil Apo-gemfibrozil Gemfibrozil Tab 600mg Lopid Dom-gemfibrozil Gemfibrozil-600 - Tab 600mg Teva-gemfibrozil Scheinpharm Gemfibrozil Gemfibrozil-300 - Cap Nu-gemfibrozil Tab 600mg Riva-gemfibrozil
Indication	Gemfibrozil is indicated to treat patients with Types IV and V hyperlipidemia who have elevated serum triglycerides (usually above 2000mg/dL), elevated VLDL cholesterol, fasting chylomicrons, are at risk of developing pancreatitis, and do not adequately respond to dietary restrictions.[L8525] Gemfibrozil is also indicated to reduce the risk of developing coronary heart disease in patients with Type IIb hyperlipidemia without history or symptoms of coronary heart disease; who do not adequately respond to weight loss, diet, exercise, and other medications; and have low HDL, raised LDL, and raised triglycerides.[L8525]
Categories	Acids, Acyclic Agents Causing Muscle Toxicity Benzene Derivatives Butyrates Chemically-Induced Disorders Cytochrome P-450 CYP1A2 Inhibitors Cytochrome P-450 CYP1A2 Inhibitors (strength unknown) Cytochrome P-450 CYP2C19 Inhibitors Cytochrome P-450 CYP2C19 Inhibitors (strong) Cytochrome P-450 CYP2C8 Inducers Cytochrome P-450 CYP2C8 Inducers (strength unknown) Cytochrome P-450 CYP2C8 Inhibitors Cytochrome P-450 CYP2C8 Inhibitors (strong) Cytochrome P-450 CYP2C9 Inhibitors Cytochrome P-450 CYP2C9 Inhibitors (strong) Cytochrome P-450 CYP3A Substrates Cytochrome P-450 CYP3A4 Substrates Cytochrome P-450 Enzyme Inducers Cytochrome P-450 Enzyme Inhibitors Cytochrome P-450 Substrates Drugs causing inadvertant photosensitivity Drugs that are Mainly Renally Excreted Enzyme Inhibitors Ethers Fatty Acids Fatty Acids, Volatile Fibric Acid Derivatives Fibric Acids Hypolipidemic Agents Hypolipidemic Agents Indicated for Hyperlipidemia Isobutyrates Lipid Modifying Agents Lipid Modifying Agents, Plain Lipid Regulating Agents Lipids Non-statin Hypolipidemic Agents Indicated for Hyperlipidemia Noxae OAT3/SLC22A8 Inhibitors OATP1B1/SLCO1B1 Inhibitors OATP1B3 inhibitors Organic Anion Transporting Polypeptide 2B1 Inhibitors Pentanoic Acids Peroxisome Proliferator Receptor alpha Agonist Peroxisome Proliferator-activated Receptor alpha Agonists Phenols Phenyl Ethers Photosensitizing Agents Toxic Actions UGT1A1 Inhibitors UGT1A1 Substrates UGT1A3 Inhibitors UGT1A3 substrates UGT1A9 Substrates UGT2B17 substrates UGT2B7 substrates Valerates
ATC-Code	C10AB04
CAS number	25812-30-0

Drug Targets

Name	Target Sequence	Pharmacological Action	Actions
Peroxisome proliferator-activated receptor alpha	MVDTESPLCPLSPLEAGDLESPLSEEFLQEMGNIQEISQSIGEDSSGSFG...	unknown	agonist
Lipoprotein lipase	MESKALLVLTLAVWLQSLTASRGGVAAADQRRDFIDIESKFALRTPEDTA...	unknown	activator
Solute carrier organic anion transporter family member 1B1	MDQNQHLNKTAEAQPSENKKTRYCNGLKMFLAALSLSFIAKTLGAIIMKS...	unknown	inhibitor
Organic anion transporter 3	MTFSEILDRVGSMGHFQFLHVAILGLPILNMANHNLLQIFTAATPVHHCR...	unknown	inhibitor
Solute carrier organic anion transporter family member 2B1	MGPRIGPAGEVPQVPDKETKATMGTENTPGGKASPDPQDVRPSVFHNIKL...	unknown	inhibitor
Solute carrier organic anion transporter family member 1B3	MDQHQHLNKTAESASSEKKKTRRCNGFKMFLAALSFSYIAKALGGIIMKI...	unknown	inhibitor
Cytochrome P450 2C8	MEPFVVLVLCLSFMLLFSLWRQSCRRRKLPPGPTPLPIIGNMLQIDVKDI...	unknown	inhibitor
Cytochrome P450 2C19	MDPFVVLVLCLSCLLLLSIWRQSSGRGKLPPGPTPLPVIGNILQIDIKDV...	unknown	inhibitor
Cytochrome P450 2C9	MDSLVVLVLCLSCLLLLSLWRQSSGRGKLPPGPTPLPVIGNILQIGIKDI...	unknown	inhibitor
Cytochrome P450 1A2	MALSQSVPFSATELLLASAIFCLVFWVLKGLRPRVPKGLKSPPEPWGWPL...	unknown	inhibitor
Cytochrome P450 3A4	MALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNI...	unknown	substrate
UDP-glucuronosyltransferase 2B7	MSVKWTSVILLIQLSFCFSSGNCGKVLVWAAEYSHWMNIKTILDELIQRG...	unknown	substrate
UDP-glucuronosyltransferase 1A1	MAVESQGGRPLVLGLLLCVLGPVVSHAGKILLIPVDGSHWLSMLGAIQQL...	unknown	substrate,inhibitor
UDP-glucuronosyltransferase 1A3	MATGLQVPLPWLATGLLLLLSVQPWAESGKVLVVPIDGSHWLSMREVLRE...	unknown	substrate,inhibitor
UDP-glucuronosyltransferase 1A9	MACTGWTSPLPLCVCLLLTCGFAEAGKLLVVPMDGSHWFTMRSVVEKLIL...	unknown	substrate
UDP-glucuronosyltransferase 2B4	MSMKWTSALLLIQLSCYFSSGSCGKVLVWPTEFSHWMNIKTILDELVQRG...	unknown	substrate
UDP-glucuronosyltransferase 2B17	MSLKWMSVFLLMQLSCYFSSGSCGKVLVWPTEYSHWINMKTILEELVQRG...	unknown	substrate
Albumin	MKWVTFISLLFLFSSAYSRGVFRRDAHKSEVAHRFKDLGEENFKALVLIA...	unknown	binder
View More

Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682